The Covid-19 antibody test will be accessible through Tasso’s remote blood collection device and new Tasso+ in-clinic collections. Credit: Rako Science.

Pictor is set to introduce its PictArray SARS-CoV-2 IgG enzyme-linked immunosorbent assay (ELISA) antibody test in New Zealand.

The company will collaborate with Rako Science to provide improved access to Covid-19 antibody testing in the country using Tasso technology.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The Covid-19 antibody test will be accessible through Tasso’s remote blood collection device and new Tasso+ in-clinic collections.

New Zealanders and healthcare organisations will be able to access the ELISA antibody test from Rako Science.

Initially, Rako Science will provide supervised in-centre testing from two locations in Christchurch and Auckland.

See Also:

Claimed to be the first of its kind, the PictArray SARS-CoV-2 ELISA assay has been designed for detecting if a patient’s body generates an immune response to Covid-19.

It can also detect if a patient has antibodies from a previous SARS-CoV-2 infection, from spike protein (SP) and nucleocapsid protein (NP) antibodies, or from vaccination alone, which generates SP antibodies only.

This test will help indicate whether patients who are at risk were not able to mount a detectable antibody response despite vaccination or infection (SP and NP negative).

Pictor CEO Howard Moore said: “The ability to test for SP, NP and a combination of SP and NP allows us to understand an individual’s circulating antibodies.

“That way, the patient and their doctor will know whether the patient should be immunised or boosted.”

The PictArray SARS-CoV-2 ELISA assay helps to guide personalised clinical interventions and inform broader measures related to public health.

In June, Pictor obtained CE mark for the PictArray SARS-CoV-2 IgG ELISA antibody test.